WO2008002152A2 - Process for culturing bacteria of the piscirickettsia genus - Google Patents
Process for culturing bacteria of the piscirickettsia genus Download PDFInfo
- Publication number
- WO2008002152A2 WO2008002152A2 PCT/NO2007/000239 NO2007000239W WO2008002152A2 WO 2008002152 A2 WO2008002152 A2 WO 2008002152A2 NO 2007000239 W NO2007000239 W NO 2007000239W WO 2008002152 A2 WO2008002152 A2 WO 2008002152A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bacterium
- bacteria
- vaccine
- piscirickettsia
- genus
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 239
- 238000000034 method Methods 0.000 title claims abstract description 113
- 230000008569 process Effects 0.000 title claims abstract description 88
- 241000192127 Piscirickettsia Species 0.000 title claims abstract description 84
- 238000012258 culturing Methods 0.000 title claims abstract description 23
- 229960005486 vaccine Drugs 0.000 claims abstract description 72
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims abstract description 6
- 241000192126 Piscirickettsia salmonis Species 0.000 claims description 56
- 241000251468 Actinopterygii Species 0.000 claims description 44
- 235000019688 fish Nutrition 0.000 claims description 43
- 230000001580 bacterial effect Effects 0.000 claims description 39
- 239000002609 medium Substances 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 208000037113 Piscirickettsiaceae Infections Diseases 0.000 claims description 15
- 238000010790 dilution Methods 0.000 claims description 15
- 239000012895 dilution Substances 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 230000000890 antigenic effect Effects 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 108091023242 Internal transcribed spacer Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 claims description 8
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000000644 propagated effect Effects 0.000 claims description 7
- 230000002238 attenuated effect Effects 0.000 claims description 6
- 238000003306 harvesting Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 230000002538 fungal effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 claims description 4
- 241000546112 Infectious salmon anemia virus Species 0.000 claims description 4
- 102000011931 Nucleoproteins Human genes 0.000 claims description 4
- 108010061100 Nucleoproteins Proteins 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000011026 diafiltration Methods 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 230000017074 necrotic cell death Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 241000700723 Ictalurid herpesvirus 1 Species 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 238000009295 crossflow filtration Methods 0.000 claims description 3
- 230000000670 limiting effect Effects 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 2
- 241000186312 Brevibacterium sp. Species 0.000 claims description 2
- 241001611011 Caligus Species 0.000 claims description 2
- 108090000565 Capsid Proteins Proteins 0.000 claims description 2
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 2
- 241000252233 Cyprinus carpio Species 0.000 claims description 2
- 241001148513 Cytophaga sp. Species 0.000 claims description 2
- 241000589564 Flavobacterium sp. Species 0.000 claims description 2
- 241000589601 Francisella Species 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 241000248484 Ichthyophthirius Species 0.000 claims description 2
- 241000701372 Iridovirus Species 0.000 claims description 2
- 241001661732 Isavirus Species 0.000 claims description 2
- 241000178948 Lactococcus sp. Species 0.000 claims description 2
- 241001247233 Lepeophtheirus Species 0.000 claims description 2
- 241001627205 Leuconostoc sp. Species 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 241001600139 Moritella viscosa Species 0.000 claims description 2
- 201000002481 Myositis Diseases 0.000 claims description 2
- 241000187681 Nocardia sp. Species 0.000 claims description 2
- 208000016222 Pancreatic disease Diseases 0.000 claims description 2
- 241000604136 Pediococcus sp. Species 0.000 claims description 2
- 241001517016 Photobacterium damselae Species 0.000 claims description 2
- 241000589774 Pseudomonas sp. Species 0.000 claims description 2
- 241000952573 Renibacterium sp. Species 0.000 claims description 2
- 241001385942 Saprolegnia sp. Species 0.000 claims description 2
- 241000194022 Streptococcus sp. Species 0.000 claims description 2
- 101710172711 Structural protein Proteins 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 241000607284 Vibrio sp. Species 0.000 claims description 2
- 206010058874 Viraemia Diseases 0.000 claims description 2
- 241000131891 Yersinia sp. Species 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007928 intraperitoneal injection Substances 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 239000007320 rich medium Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 210000002027 skeletal muscle Anatomy 0.000 claims description 2
- ABQGFYSYSCHJNB-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(pyridin-2-yldisulfanyl)pentanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCSSC1=CC=CC=N1 ABQGFYSYSCHJNB-UHFFFAOYSA-N 0.000 claims 1
- 241000607519 Aeromonas sp. Species 0.000 claims 1
- 241001660014 Salmon pancreas disease virus Species 0.000 claims 1
- 241001609931 bacterium 20 Species 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 56
- 239000000725 suspension Substances 0.000 description 27
- 230000003287 optical effect Effects 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 241000277331 Salmonidae Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241001135139 Vibrio ordalii Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 108020004418 ribosomal RNA Proteins 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 241000606651 Rickettsiales Species 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001519451 Abramis brama Species 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001434006 Atractoscion nobilis Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 101150035271 CHSE gene Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- -1 Cremophore Chemical class 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000276457 Gadidae Species 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001417534 Lutjanidae Species 0.000 description 1
- 101000883840 Macrobrachium rosenbergii Crustacean hyperglycemic hormone isoform 1 Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000277338 Oncorhynchus kisutch Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001454698 Teleostei Species 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- JLQUFIHWVLZVTJ-UHFFFAOYSA-N carbosulfan Chemical compound CCCCN(CCCC)SN(C)C(=O)OC1=CC=CC2=C1OC(C)(C)C2 JLQUFIHWVLZVTJ-UHFFFAOYSA-N 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001853 pulsed-field electrophoresis Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 108700022487 rRNA Genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 241001507086 salmonid fish Species 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0233—Rickettsiales, e.g. Anaplasma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present application provides processes for culturing bacteria belonging to the Piscirickettsia genus, processes for selecting/identifying such bacteria as well as processes for manufacturing vaccines. The invention further provides vaccine compositions and formulations and bacteria that are identified and/or cultured by a process according to the invention.
Description
PROCESS FOR CULTURING BACTERIA OF THE PISCIRICKETTSIA GENUS
FIELD OF INVENTION
The present invention relates to the identification and culturing of particular isolates of bacteria belonging to the Piscirickettsia genus and to vaccines based on these bacterial isolates.
BACKGROUND OF THE INVENTION
A novel disease of fish, Salmonid rickettsial septicemia (SRS), or piscirickettsiosis, was observed in 1989 among choho salmon, Oπcorhynchus kisutch (Walbaum) in Chile (Bravo & Campos 1989). The first signs of disease began 6-12 weeks after fish were transferred from fresh water to sea water, and cumulative mortality ranged from 30 to 90% (Bravo & Campos 1989). Anaemia caused by the systemic spread and replication of an intracellular bacterium was the principal characteristic of the disease (Cvitanich, Garate & Smith 1991). The gram-negative intracellular bacterium was initially referred to as rickettsia-like (Fryer et al. 1990; Cvitanich et al. 1991) and was later grouped in the Gammaproteobacteria and assigned to a new genus and species Piscirickettsia salmonis by Fryer, Lannan, Giovannoni & Wood (1992).
Some non-salmonid fish have been confirmed to be infected with P. salmonis; white seabass from California, USA (Chen et al. 2000) and European seabass (McCarthy et al. 2005).
In early studies, P. salmonis bacteria failed to grow on a number of artificial bacteriological media and the bacteria were thus considered to be obligate intracellular organisms. It was observed, however, that the bacteria are able to propagate on a number of cell lines of salmon and non-salmonid origin, i.e. CHSE- 214, CHH-I, CSE-119, TRG-2, EPC, and FHM (Cvitanich et al. 1991, Fryer et al. 1990 and 1992). More recent studies have shown that the bacteria have the ability to replicate in Sf-9 insect cells (Birkbeck et al. 2004). The organism is capable of replication between 10-21 C0. P. salmonis produces a cytopathic effect causing cytoplasmic vacuolation and rounding of infected cells. P. salmonis is still
capable of reproducing the disease after nine passes in cell culture when injected into salmon (House et al. 1999).
Initial attempts to utilize whole cell bacterins to protect salmon from P. salmonis infection have shown variable results. In trials using formalin inactivated bacterin without adjuvant, Smith, et al. (1995 and 1997) demonstrated significant protection to natural challenges with the bacterium, while fish receiving adjuvant and bacterin in the same trial showed no protection, or a greater susceptibility to infection. In other trials increased survival was observed when coho salmon were injected with whole cell bacterins in oil and water adjuvants (Kuzyk et al. 2001a). However, better protection was observed with a vaccine prepared with recombinant OspA alone or fused with T cell epitopes from tetanus toxin and measles fusion protein (Kuzyk et al. 2001b). Although there are commercial vaccines on the market today, piscirickettsiosis remains a major problem, in particular in the South American salmonid farming industry. Bacteria similar to P. salmonis have, and probably will, continue to be isolated from a number of new fish species over a wide geographic range including in more temperate sea water conditions. Together with closely related bacteria, P. salmonis may have a wide host and geographical range, which clearly suggests that an efficient protection against infection with bacteria of the genus will be important for the fish farming industry.
However, with the current knowledge on processes for producing P. salmonis antigen for vaccines against piscirikettsiosis, the manufacturers would solely rely on culturing the bacteria on suitable cell lines. This clearly provides limitations for large-scale production, since large-scale culture of P. salmonis in eukaryotic cell lines is laborious and expensive, and is not considered profitable for the fish industry.
Hence, an improved process for the production of P. salmonis antigen for piscirickettsiosis vaccines would be advantageous, and in particular a more efficient and cost effective process would be very useful for the providers of vaccines for farmed fish.
SUMMARY OF THE INVENTION
A main aspect of the present invention pertains to a process for culturing a bacterium belonging to the Piscirickettsia genus wherein said bacterium is cultured in a substantially extracellular environment. A general feature of the process is the selection for bacteria that will reproduce in an extracellular environment.
In a related aspect, the invention provides a process for producing a vaccine comprising one or more steps of culturing a bacterium of the Piscirickettsia genus, wherein the bacterium is cultured in a substantially extracellular environment. Another aspect of the invention provides a process for obtaining a bacterium belonging to the Piscirickettsia genus, which in some embodiments comprises the steps of: a) providing a sample from a fish, which is infected with bacteria belonging to the Piscirickettsia genus; b) inoculating into an essentially cell free culture medium bacteria from said sample or dilution series hereof, or bacteria from a spread plate culture established from said sample or dilution series hereof; and c) selecting a bacterium that propagate freely in the medium.
Yet another main aspect of the invention provides a bacterium of the Piscirickettsia genus, said bacterium having the ability to propagate in a substantially extracellular environment. In some embodiments the bacterium may be characterised as being one that is obtainable by the described process for obtaining a bacterium belonging to the Piscirickettsia genus.
A further important aspect pertains to a vaccine comprising a bacterium according to the invention. In a related aspect the vaccine is provided in the form of a feed.
Additional aspects of the invention relate to a bacterium according to the invention or a subunit hereof for use in veterinary medicine.
A still further aspect relates to the use of a bacterium according to the invention or a subunit of said bacterium in the manufacture of a medicament for the prevention of infections with bacteria of the Piscirickettsia genus.
Finally, the invention provides a method for prevention of infections in fish with bacteria of the Piscirickettsia genus, said method comprising administering to the fish a vaccine according to the invention.
DETAILED DESCRIPTION OF THE INVENTION
Bacteria belonging to the Piscirickettsia genus, as represented by Piscirickettsia salmonis, have been identified as the causative agent of Salmonid rickettsial septicemia (SRS), or piscirickettsiosis. The bacteria were believed to be highly fastidious obligate intracellular bacteria in agreement with the finding that they replicate within membrane-bound cytoplasmic vacuoles in tissue culture cells or those of the host fish. The present invention, however, is based on the surprising finding that it is possible to obtain isolates of bacteria of the Piscirikettsia genus that are capable of growing in an extracellular environment.
Based on this unexpected finding it was possible to provide a process where bacteria belonging to the Piscirickettsia genus are cultured and harvested in process steps and under conditions that favour bacteria which are capable of growing in an extracellular or cell free environment. Thus, in its broadest sense, the invention therefore pertains to a process for culturing a bacterium belonging to the Piscirickettsia genus (Piscirickettsia spp. j, and one of the advantages of the present process is that it comprises one or more steps during which bacteria that are capable of growing in an extracellular environment will be selected. In the process of the invention a selection pressure may be established by culturing the bacteria without any host cells or cells of non-mammalian origin or with a number of host cells that are considered inadequate to sustain intracellular growth of a sufficient number of bacteria. During the process, further steps selecting for extracellular bacterial growth may be conducted. These may include harvesting the cultured bacteria from the culture medium directly and under non-lysing conditions, i.e. conditions that are not set to cause lysis of cells of non-bacteral origin. Thus, whether some cells of non-bacterial origin are present in the culture
medium is immaterial, as the process does not rely on the capacity of these cells to act as host cells for the bacteria.
Thus, in a main aspect, the invention pertains to a process for culturing a bacterium belonging to the Piscirickettsia genus (Piscirickettsia spp.) wherein the 5 bacterium is propagated or cultured in a substantially extracellular environment. Thus, in the context of the present invention, the term "in a substantially extracellular environment" further refers to a culture of bacteria, wherein at least 10%, such as at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 98, 99, 99.5 or 100% of the bacteria propagate freely in the medium.
10 In one embodiment of the process of the invention, the bacterium is propagated (cultured) substantially in the absence of cells of non-bacterial origin. It will be understood that cells of non-bacterial origin comprise vertebrate cells, such as cells that would otherwise be suitable as host cells for a bacterium belonging to the Piscirickettsia genus. Thus, within the scope of the present invention, is a
15 process is provided wherein a bacterium belonging to the Piscirickettsia genus is cultured in a process that does not rely on the use of host cells.
In the present context the terms "in a substantially extracellular environment" and "substantially in the absence of cells of non-bacterial origin" define a culture of bacteria, wherein bacteria are cultured to a TCID50 titre of at least 1 x 104
20 bacteria/ml medium, such as at least 1 x 104, at least 5 x 104, at least 1 x 105, at least 5 x 105, at least 1 x 106, at least 5 x 106, at least 1 x 107, at least 5 x 107, at least 1 x 108, least 5 x 108, least 1 x 109, at least 2 x 109, at least 3 x 109, at least 4 x 109, at least 5 x 109, at least 6 x 109, at least 7 x 109, at least 8 x 109, at least 9 x 109, at least 1 x 1010, at least 2 x 1010, at least 3 x 1010, at least 4 x
25 1010, or such as at least 5 x 1010 bacteria/ml medium in the presence of at the most 10s cells of non-bacterial origin/ml culture medium, such as at the most 2 x 105, such as at the most 3 x 105, at the most 4 x 10s, at the most 5 x 105, at the most, 6 x 10s, at the most 7 x 105, at the most 8 x 10s, at the most 9 x 105, or such as in the presence of at the most 1 x 106 cells of non-bacterial origin/ml
30 culture medium. The culture may be established by inoculating a culture with a volume of a stock solution corresponding preferably to 0.25 to 4%, more preferably 0.5 to 2%, most preferably 1% of the of the final volume of medium in said culture and having an optical density of between 2.5 and 3.5, such as an
optical density of 2.8 or 2.9. For this purpose the bacteria may be cultured in ventilated spinner flasks, preferably at 30-200 RPM and a temperature of 18.5 to 19.50C for a period of from 1-10 days, such as from 1 to 8 days, such as from 2 to 5 days, such as from 2 to 4 days, such as from 2 to 3 days. Alternatively, P.salmonis can be grown in shaker flasks or in static cultures.
In an embodiment of the process of the invention, the process is one for culturing a bacterium belonging to the Piscirickettsia genus, wherein a substantial amount of the bacteria are propagated/cultured in an extracellular environment
An initial step of the process according to the invention may involve establishing a stock suspension of bacteria from a selected bacterial isolate. It is contemplated that the stock suspension may be established by selecting bacteria from primary isolates that are capable of propagating in an extracellular environment.
The stock suspension may contain bacteria of the Piscirikettsia genus in amounts of 105, 106, 107, 10s, 109, 1010, 1011 TCID50AnI. The TCID50 unit is defined as that dilution of a virus required to infect 50% of a given batch of inoculated cell cultures. The stock suspension can be frozen with a cryoprotectant such as DMSO, glycerol or others, and be kept for prolonged times at -800C.
Thus, in a preferred embodiment, the process according to the invention thus comprises establishing a stock suspension by a process comprising the steps of: a) providing a sample from a fish, which is infected with bacteria belonging to the Piscirickettsia genus; b) inoculating into a culture medium, which is preferably essentially cell free, bacteria from said sample or dilution series hereof, or bacteria from a spread plate culture established from said sample or dilution series hereof; and c) selecting bacteria that propagate freely in the medium.
In preferred embodiments of the present invention the bacterium belonging to the Piscirickettsia genus is a bacterium that has the ability to introduce the symptoms and disease of piscirickettsiosis in a fish. External symptoms of piscirickettsiosis include: dark colour, anorexia and lethargia, erratic swimming due to infections in
the brain, skin lesions that can progress to shallow ulcersas well as pale gills resulting from significant anaemia. Internal symptoms include swollen and discoloured kidney, an enlarged spleen, ascites in the peritoneum, haemorrhages on the visceral fat, stomach, swim bladder, and body musculature, as well as whitish or yellow, multifocal, coalescing, pyogranulomatous nodules found in the liver. Further internal symptoms in the liver include multifocal necrosis of hepatocytes, accompanied by a chronic inflammatory infiltrate of mononuclear cells, vascular and perivascular necrosis and intravascular coagulation resulting in fibrin thrombi within major vessels. In the kidney and spleen, vascular changes similar to those in the liver may also be observed, and granulomatous inflammation also occurs in the interstitium and parenchyma of the kidney and spleen, respectively. Meningitis, endocarditis, peritonitis, pancreatitis, and branchitis may be observed with accompanying chronic inflammatory and vascular changes similar to those in the liver and haematopoietic organs.
High magnification examination of lesions reveals aggregates of the organism in the cytoplasm of degenerated hepatocytes and in macrophages. Infected macrophages are usually hypertrophied and replete with cellular debris. In tissue sections stained with haematoxylin and eosin, the organism appears as basophilic or amphophilic spheres, about 1 μm in diameter.
For the purpose of the present invention, a presumptive diagnosis of fish, which are infected with bacteria belonging to the Pisciήckettsia genus, may be by visualization of the causative agent within macrophages or hepatocytes in histological sections or tissue imprints. As a means of confirmatory diagnosis, PCR assays can also be conducted directly on isolated tissues (Marshal et a!., 1998, Mauel et al. 1996, both incorporated herein by reference in their entirety), and thus PCR assays on tissues along with the observation of suspect organisms within macrophages or hepatocytes are suitable methods for confirmatory diagnosis. Bacteriological culture on cystein heart agar supplemented with 5% sheep blood can also be used as a means of diagnosis. P.salmonis will usually appear as whitish streaks on the plate, and may also form single colonies. Alternatively, Piscirickettsia spp. can be detected with Giemsa-stained tissue smears, followed by indirect immunofluorescent antibody test (IFAT), polymerase
chain reaction (PCR) with relevant primers and/or nucleic acid sequencing for positive identification. These are techniques which are known by the skilled person in the art.
A series of standard monitoring methods and diagnostic methods for piscirickettsiosis have been developed by the World Organization for Animal Health as published in the Manual of Diagnostic tests for Aquatic Animals 2003, part 2, section 2.1, chapter 2.1.13, the content of which is incorporated herein by reference.
Infected fish tissues suitable for examination in IFAT, PCR, tissue imprints and histology are kidney, liver and blood, collected from diseased fish during either overt or covert infections. Due to sensitivity of P. salmonis to antibiotics in vitro, none should be used in media during collection of tissue or the culture of cells.
Similarly, the tissues mentioned above provide suitable sources for samples to be used in the process of isolating a bacterium of the Piscirickettsia genus and for establishing a stock suspension of Piscirickettsia spp. according to the present invention. Accordingly, preferred embodiments of the invention pertains to a process, wherein said sample is taken from a body tissue, a body fluid, a secretion or, preferably, from a tissue homogenate. In a further preferred embodiment the tissue homogenate has been clarified by centrifugation or filtration. In a further preferred embodiment of the invention, the selected bacterium is further cultured over at least 1, such as at least 2, at least 3, at least 4, at least 5, at least 10, at least 11, at least 12, at least 13, at least 14, or at least 15 passages before a stock suspension is established.
As mentioned, the present invention pertains to a process of culturing a bacterium which is capable of introducing the symptoms and disease of piscirickettsiosis. For the purpose of determining whether a bacterium belonging to the Piscirickettsia genus may cause the disease and symptoms of piscirickettsiosis, experiments may be conducted in which Atlantic salmon weighing 20-40 grams are challenged intraperitoneally in fresh water with 10-fold dilutions of Piscirickettsia spp. cultures. Preferably, the cultures should have a titre of at least 10s TCID50/ml Piscirickettsia spp. The fish should be observed daily for the next five weeks, and
should display the above-mentioned symptoms of piscirickettsiosis within this time.
As of present, bacteria of the species Piscirickettsia salmonis have been identified as causative agents of piscirickettsiosis. Accordingly, for the purpose of the present invention it may be preferred that the bacterium cultured in the process of the invention is of the species Piscirickettsia salmonis.
As described in the below Examples, stock suspensions have been established from a number of isolates of Piscirickettsia spp that have been selected for the ability to grow in an extracellular environment. Samples from representative isolates have been deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the following accession numbers: 06050901 (isolate AL10005), 06050902 (isolate AL10007), and 06050903 (isolate AL10008). A further representative sample has been deposited on 21 March 2007 under the accession number 07032110 (isolate
Comment [MRl]: Dennβ er
AL10014). deponert en annen dato enn nevnt Marit, vil du tilføje den rigb'ge deponeringsdato
In preferred embodiments of the invention relating to the process, said bacterium belonging to the Piscirickettsia genus thus has genotypic and/or phenotypic characteristics related to those of any of the bacteria which are deposited in the European Collection of Cell Culture (ECACC) Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 june 2006 under the following provisional accession numbers: 06050901 (isolate AL10005), 06050902 (isolate AL10007), 06050903 (isolate AL10008) or to those of the bacteria deposited on 21 March 2007 under the accession number 07032110 (isolate ALlOO 14).
Specific genotypic characteristics which are often used for distinguishing between bacterial species and isolates are the sequences of their internal transcribed spacers (ITS) and the sequences of the genes coding for the 16S and 23S ribosomal RNAs. The ITS are non-coding regions of DNA sequence that separate genes coding for the 16S and 23S ribosomal RNAs. These ribosomal RNA (rRNA) genes are relatively conserved across taxa and species while the spacers between them may be specific for particular species and isolates. The conservation of the
rRNA genes allows for easy access to the ITS regions with "versatile" primers for polymerase chain reaction (PCR) amplification. The inventors have found that the isolates of bacteria belonging to the Piscirickettsia genus which are able to grow substantially in the absence of cells of non-bacterial origin have ITS sequences that can be as little as 95%, 96%, 97%, 98% or 99% identical to those of isolates that are obligate intracellular bacteria. Thus, a preferred embodiment of the invention relates to a process, wherein said bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises a nucleic acid sequence which is more than 95% identical to the sequence:
GTATAAGTAAAGATTCCTTGATTMTTTAGGGTTATΓΓTTATTTTCGATTGAGATGTATTTT
TATGTTTTGATTGATAAATGGGAATAA I I I I I AGTTTATTTAATTAACGAGTCTTGGTAATT TTTGAAAACCGGTGTTGAGATATAGTTTTGATTGGTTTTAGTTAATAGATTTTAGATTTATT GATATAAGAC I I I I I GGGGTTATATGATCAAGTGAATAAGTGCAT (SEQ ID. NO. 1). In further specific embodiments said bacterium belonging to the Piscirickettsia genus is characterised by having an 16S rRNA gene which comprises a nucleic acid sequence which is at least 97% identical to the sequence:
GTATAAGTAAAGATTCCTTGATTAATTTAGGGTTA n 1 1 1 ATΓTTCGATTGAGATGTATTTT TATGTTTTGATTGATAAATGGGAATAA I I I I I AGTTTATTTAATTAACGAGTCTTGGTAATT TTTGAAMCCGGTGTTGAGATATAGTTTΓGATTGGTTTTAGTTAATAGATTTTAGATTTATT GATATAAGAC I I I I I GGGGTTATATGATCAAGTGAATAAGTGCAT (SEQ ID. NO. 1), such as at least 97,0%, at least 97,2%, at least 97,3%, at least 97,4%, at least 97,5%, at least 97,6%, such as at least 97,7%, at least 97,8%, at least 97,9%, at least 98%, at least 99%%, at least 100%, identical to said sequence. The term "sequence identity" indicates a quantitative measure of the degree of homology between two amino acid sequences or between two nucleic acid sequences of equal length. If the two sequences to be compared are not of equal length, they must be aligned to give the best possible fit, allowing the insertion of gaps or, alternatively, truncation at the ends of the polypeptide sequences or
nucleotide sequences. The sequence identity can be calculated as Nnf , wherein Ndif is the total number of non-identical residues in the two sequences when aligned and wherein Nref is the number of residues in one of the sequences. Hence, the DNA sequence AGTCAGTC will have a sequence identity of 75% with
the sequence AATCAATC (Ndif=2 and Nref=8). A gap is counted as non-identity of the specific residue(s), i.e. the DNA sequence AGTGTC will have a sequence identity of 75% with the DNA sequence AGTCAGTC (Ndif=2 and Nref=8).
With respect all embodiments of the invention relating to nucleotide sequences, the percentage of sequence identity between one or more sequences may also be based on alignments using the clustalW software
(http:/www.ebi. ac.uk/clustalW/index. html) with default settings. For nucleotide sequence alignments these settings are: Alignment=3Dfull, Gap Open 10.00, Gap Ext. 0.20, Gap separation Dist. 4, DNA weight matrix: identity (IUB). Alternatively, and as illustrated in the examples, nucleotide sequences may be analysed using programme DNASIS Max and the comparison of the sequences may be done at http://www.paraliqn.org/. This service is based on the two comparison algorithms called Smith-Waterman (SW) and ParAlign. The first algorithm was published by Smith and Waterman (1981) and is a well established method that finds the optimal local alignment of two sequences. The other algorithm, ParAlign, is a heuristic method for sequence alignment; details on the method is published in Rognes (2001). Default settings for score matrix and Gap penalties as well as E-values were used.
In further preferred embodiments of the present invention, said bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises the sequence of SEQ ID NO: 1.
The bacterium belonging to the Piscirickettsia genus may be further characterised by having a 16S rRNA gene which comprises a nucleic acid sequence which is at least 95,0% identical to the sequence of SEQ ID. NO. 2, such as at least 95,1%, at least 95,2%, at least 95,3%, at least 95,4%, at least 95,5%, at least 95,6%, such as at least 95,7%, at least 95,8%, at least 95,9%, at least 96%, at least 97%, at least 98%, at least 99%, or such as at least 99.5% identical to the sequence of SEQ ID. NO. 2. In particular embodiments the 16S rRNA gene comprises a sequence which is identical to that of an isolate of obligate intracellular bacteria of the Piscirickettsia salmonis species. Accordingly, in an embodiment of the process according to the invention, said bacterium belonging to the Piscirickettsia genus may be further characterised by having a 16S rRNA
gene, which comprises the sequence
ATCCATAGCTGGTTTGAGAGAATGGCCAGCCACACTGGGACTGAGACACGGCCCAGACT CCTACGGGAGGCAGCAGTGGGGAATATTGGACAATGGGGGGAACCCTGATCCAGCAAT GCCACGTGTGTGAAGAAGGCCTTAGGGTTGTAAAGCACTTTCAGCGGGGAGGAAGGTAA GCTAATTAATACTTGGCTTAATTGACGTTACCTGCAGAAGAAGCACCGGCTAACTCCGTG CCAGCAGCCGCGGTAATACGGAGGGTGCGAGCGTTAATCGGAATTACTGGGCGTAAAG GGCGCGTAGGCGGAAGATTAAGTTGGATGTGAAATCCCAGGGCTCAACCTTGGAACTGC ATCCGAAACTGGTATTCTAGAGTATGGTAGAGGAAAGTGGTTTCGCAGGTGTA (SEQ ID NO: 2). The sequences of the 16S rRNA of a bacterium belonging to the Piscirickettsia genus may be amplified in a nested PCR procedure using primers according to Mauel et al, 1996. These primers amplify a conserved region of the Piscirickettsia salmonis 16S rRNA gene. For amplification of a 283 base pair sequence from the ITS region, primers according to Marshall et al., 1998 are used. Other specific genotypic characteristics comprise a Pulsed Field Gel
Electrophoresis PFGE band pattern as shown in Figure 2 for isolate AL 10007 (accession number 06050902). Specific phenotypic characteristics comprise a band pattern similar to that seen with AL 10005 (accession number 06050901) when performing Western blotting with an ant\-P.salmonis antibody. In the presently most preferred embodiment(s), said bacteria belonging to the Piscirickettsia genus is any of the bacteria, which are deposited deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the following accession numbers: 06050901 (isolate AL10005), 06050902 (isolate AL10007) and 06050903 (isolate AL10008) or the bacteria which are deposited on 21 March 2007 under the accession number 07032110 (isolate AL10014).
A bacterial stock suspension as described above provides a source of bacteria for the bacterial culture that is eventually established for production of the bacterium belonging to the Piscirickettsia genus. In the process of the present invention it may however be preferred to culture the bacteria of the stock suspension in one or more pre-cultures before eventually transferring the cells to the production
culture. In particular, this is relevant when production of the bacteria is performed in large scale, such as in industrial scale.
In further preferred embodiments relating to the process of the invention, the bacterium is propagated at a temperature of between 10 and 250C, preferably at a temperature of between 12 and 23 0C, more preferably of between 15 and 220C, even more preferably of between 17 and 210C, still more preferably of between 18 and 2O0C and most preferably at a temperature of between 18.5 and 19.5°C.
In equally preferred embodiments, the bacterium is propagated at a pH of between 5.5 and 8.0, more preferably of between 5.7 and 7.0, even more preferably of between 5.9 and 6.8, still more preferably of between 6.1 and 6.6, and most preferably between 6.2 and 6.5.
It is contemplated that higher titres of bacteria may be obtained when the pH in the culture is tightly controlled. Suitable means for controlling the pH include automatic addition of acid or base or Na2HCO3 and CO2.
Various different culture media may be used in the process according to the invention, including many commercially available media. For industrial scale production of the bacteria belonging to the Piscirikettsia genus it will in most cases be desirable to optimise the process to give a maximum output and for this and other purposes, it may be preferred to culture the bacteria in a nutrition rich medium. More specifically, it may be preferred that the medium contains one or more compounds selected from the group consisting of proteins, amino acids, carbohydrates, fatty acids, lipids and micronutrients.
In further preferred embodiments the medium is a medium for insect cells; in the
Comment [MR2]: e er currently [most greferred embodiment the bacterja are ςultured in Sf-900_ II_SFM_ _ di e edie e l e er e medium as described by Godwin and Whitford, 1993, incorporated herein by e reference in its entirety. Alternatively the Sf-900 III medium may be used. As of i r e - deren e present, both media are commercially available from Invitrogen.
i e e i
In specific embodiments of the invention the process comprises the steps of: ere e e e er ed
a) inoculating a first pre-culture with a working seed suspension or stock suspension of a bacterium belonging to the Piscirickettsia genus and
culturing the bacterium under the above-mentioned conditions until reaching an optical density (O.D.6oonm) of at least 0.7, such as at least 0.8, such as at least 0.9 such as at least 1, such as at least 2, such as at least 3, such as at least 4, such as at least 5, such as at least 6 , such as at least 7, such as at least 8, such as at least 9 or such as at least 10; b) transferring a suspension of the bacterium to a second pre-culture and culturing the bacterium under the above-mentioned conditions until reaching an optical density(O.D.60onm) of at least 0.7, such as at least 0.8 such as at least 0.9 such as at least 1, such as at least 2, such as at least 3, such as at least 4, such as at least 5, such as at least 6, such as at least 7, such as at least 8, such as at least 9 or such as at least 10; c) transferring a suspension of the bacterium to a production culture, culturing the bacterium until reaching an optical density (O.D.60onm) of minimum 3; and harvesting the bacterium. In preferred embodiments, the bacterial cells are harvested from the production culture after incubation for a period of 2-8 days, such as from 3-7 days or such as from 4-6 days, when an optical density (O.D.6oonm) of from 4-20 is reached, such as when an optical density of from 5-15 is reached, when an optical density of from 6-13 is reached, when an optical density of from 6-14 is reached or Comment [MR3]: // preferably when an optical density of from 6-l|5_ i_s_reached.L dd
Comment [MR4]:
In equally preferred embodiments the invention provides a process, wherein ere r e e r dre id r d rdh *.r e de f<* r ere i a) said first pre-culture is inoculated with a volume of stock suspension corresponding to 0.1% or more (preferably 0.25 to 4%, more preferably 0.5 to 2%) of the volume of medium in said first pre-culture; and/or b) said second pre-culture is inoculated with a volume of first pre-culture corresponding to 0.1% or more (preferably 0.25 to 4%, more preferably 0.5 to 2%) of medium in said second pre-culture in order to obtain a production culture; and/or c) said production culture is inoculated with a volume of said second pre- culture corresponding to 0.1% or more (preferably 0.25 to 4%, more preferably 0.5 to 2%) of medium volume in said production culture.
To the person of skills within the field of bacterial fermentation it will be apparent that the process of the present invention may be performed by culturing the bacterium by batch fermentation, by fed-batch fermentation as well as by continuous fermentation. At present batch fermentation is preferred, also when using the process of the invention for culturing a bacterium of the Piscirickettsia genus at industrial scale. At present, a batch volume of 100 - 5000 litres of medium is contemplated. Preferred batch sizes are from 200 - 4000 litres of medium, such as from 300 - 3000 litre of medium, or such as from 450 - 2000 litres of medium. In a second main aspect the present invention provides a process for producing a vaccine comprising one or more steps of culturing a bacterium of the Piscirickettsia genus, wherein the bacterium is propagated or cultured in a substantially extracellular environment. It is to be understood that the process for producing a vaccine may be characterised by any of the features described above in relation to the process for culturing a bacterium belonging to the Piscirickettsia genus.
The process for producing a vaccine may further comprise steps of harvesting the bacterium from the culture medium as well as steps of concentrating and/or disrupting, and inactivating the bacterium. It will be known to the skilled person that inactivated bacteria can be attained in general by chemical or by physical means. Chemical inactivation can be carried out by treatment of the bacteria for example, but not limited to, with enzymes, with formaldehyde, beta-propiolactone, or ethyleneimine or derivative thereof, with organic solvents (e.g. Triton or Tween). Physiochemical inactivation can advantageously be carried out by subjecting the bacteria to energy-rich radiation, such as UV light, gamma irradiation or X-rays. If necessary the inactivation agent can be neutralized; for example formaldehyde-inactivated preparations can be neutralized with thiosulphate. If required, the pH is subsequently returned to about 7. Inactivation of bacteria by means of physical stress, using e.g. heat or a French Press, provides a suitable starting material for the manufacturing of a vaccine. Thus, a bacterin need not necessarily be in the form of inactivated whole cells; the cells may be disrupted.
ϊn certain embodiments the process may include a step of attenuating the bacterium. Thus, in some embodiments according to the invention the bacteria have been attenuated. Several approaches for obtaining attenuated bacteria are available to the skilled person. An attenuated strain of a bacteria belonging to the Piscirickettsia genus may be generated for instance by passing the bacteria through culture a number of times, or deleting or mutating a gene involved in a biosynthetic pathway.
In preferred embodiments of the invention the step for concentrating the bacterium comprises the use of filtration techniques selected from the group consisting of: continuous cross flow filtration, diafiltration, centrifugation, or any combination hereof.
In further preferred embodiments relating to the process for producing a vaccine, a concentration factor is obtained that is larger than 0 and less than or equal to 12, such as from 1.2 to 11, from 1.4 to 10, from 1.6 to 9, from 1.8 to 8, from 2 to 7, from 2.25 to 6, from 2.5 to 5, or such as from 2.75 to 4. In a presently preferred embodiment, the concentration factor for a suspension of inactivated bacteria belonging to the Piscirickettsia genus is 2-6. The concentration factor is calculated from the total amount of antigen suspension fed to the system, divided on the product recovery including hold-up volume in the filtration unit. The "hold- up volume" is the volume of concentrate of bacteria belonging to the Piscirickettsia genus remaining in the filtration unit after collection of the concentrate.
While the vaccine may be based for instance on whole bacteria as described above it may according to some embodiments relating to the invention be preferred to develop a vaccine based on subunits of the bacterium of the Piscirickettsia genus. Therefore, in some embodiments, the process comprises one or more steps for isolation and/or purification of a subunit the bacteria.
In the context of the present invention the term "subunit" refers to any component of the bacteria which alone or in combination with others is capable of eliciting an immune response. In the present context particularly suitable subunits are those that are capable of eliciting a protective immune response. Particular examples of subunits that may be suitable in the present context are
lipopolysaccarides, proteins or peptides which are able to elicit an antibody response in fish, mice or rabbits.
In the present context, the expression a "protective immune response" refers to an immune response which results in a relative percent survival of vaccinated fish of at least 20. The relative percent survival, {1- (% mortalities in vaccinated group/% mortalities in control group)}*100, may be determined in experiments wherein a group of at least 20 fish of a relevant species is immunized intraperitoneally with 0.05 - 0.5 ml of an antigen preparation and compared to a group of fish which have received phosphate buffered saline (PBS). The fish are challenged intraperitoneally after 350-600 degree days with an appropriate amount of bacteria belonging to the Pisdrickettsia genus, such as 1,33 x 104 TCID50 Pisdrickettsia salmonis isolate AL10007. The bacteria are titrated by end point dilution by the method of Karber (1931).
The appropriate dose must be determined for each experiment by doing a pre challenge of the same stock of fish with dilutions of challenge material. The fish are followed for 30-40 days, and the number of mortalities in each group recorded The skilled person will be aware of the suitable means and measures for purification of subunits of interest. In particular embodiments of the invention the subunit is isolated or purified in a process comprising one or more steps of chromatography, in particular one or more steps of affinity chromatography. In general, a lot of guidance is provided to the skilled person by publications in the field on how to develop and perform chromatographic purification of the relevant substances. In particular the skilled person may consult publications such as "Protein purification methods; a practical approach" Eds. ELV Harris and S Angal, published in the Practical Approach Series, series editors D Rickwood & BD Hames, IRL Press, Oxford 1989, and "Affinity Chromatography; Principles and Methods, Edition AB, Published by Amersham Pharmacia Biotech. The references are hereby incorporated by reference in their entirety.
A third main aspect of the present invention pertains to a process for obtaining a bacterium belonging to the Pisdrickettsia genus. In general the process involves culturing a bacterium belonging to the Pisdrickettsia genus under conditions that favour bacteria which are capable of growing substantially in the absence of cells of non-bacterial origin as explained above. In preferred embodiments, said
process for obtaining a bacterium belonging to the Piscirickettsia genus comprises the steps of: a) providing a sample from a fish, which is infected with bacteria belonging to the Piscirickettsia genus; b) inoculating into an essentially cell free culture medium bacteria from said sample or dilution series hereof, or bacteria from a spread plate culture on a Cystein Heart Agar supplemented with 5% sheep blood, established from said sample of step (a) or dilution series hereof; and c) selecting a bacterium that propagate freely in the culture medium. In the present context the term "essentially cell free culture medium" refers to a culture medium comprising at the most 105 cells of non-bacterial origin/ml culture medium, such as at the most 2 x 105, such as at the most 3 x 10s, at the most 4 x 105, at the most 5 x 10s, at the most, 6 x 10s, at the most 7 x 10s, at the most 8 x 105, at the most 9 x 10s, or such as in the presence of at the most 1 x 106 cells of non-bacterial origin/ml culture medium. It will be understood that an "essentially cell free medium" will support growth of a bacterium belonging to the Piscirickettsia genus to the desired titres in a "substantially extracellular environment" and "substantially in the absence of cells of non-bacterial origin" as herein before defined. It is a further characteristic of the process that said sample may be taken from a body tissue, a body fluid, a secretion or from a tissue homogenate.
A further aspect of the invention pertains to a bacterium of the Piscirickettsia genus, said bacterium having the ability to propagate in a substantially extracellular environment. In the present context the term "ability to propagate in a substantially extracellular environment" means that the bacteria will grow in a suitable culture medium - as for instance the Sf-900 II SFM medium with no supplements. It is to be understood that the bacteria will grow to a titre of at least 1 x 104, at least 5 x 104, at least 1 x 105, at leats 5 x 10s, at least 1 x 106, at least 5 x 106, at least 1 x 107, at least 5 x IfJ7, at least 1 x 108, least 5 x 108, least 1 x 109, at least 2 x 109, at least 3 x 109, at least 4 x 109, at least 5 x 109, at least 6 x 109, at least 7
x 109, at least 8 x 109, at least 9 x 109, at least 1 x 1010 in a culture without cells of non-bacterial origin, established by inoculating a volume of a stock solution corresponding preferably to 0.25 to 4%, more preferably 0.5 to 2%, most preferably 0.1%) of the of the final volume of medium in said first culture and having an optical density of between 2.5 and 3.5, such as an optical density of 2.8 or 2.9. For this purpose the bacteria may be cultured for in ventilated spinner flasks at between 50 and 500 RPM and a temperature of 18.5 to 19.50C for a period of from 1-10 days, such as from 1 to 8 days, such as from 2 to 5 days, such as from 2 to 4 days, such as from 2 to 3 days. In preferred embodiments of the invention the bacterium is one that is obtainable by a process as described above. In particular the bacterium is obtainable by a process comprising the steps of: a) providing a sample from a fish, which is infected with bacteria belonging to the Piscirickettsia genus; b) inoculating into a culture medium, which is preferably essentially cell free, bacteria from said sample or dilution series hereof, or bacteria from a spread plate culture established from said sample or dilution series hereof; and c) selecting bacteria that propagate freely in the medium. In further embodiments of the invention the bacterium is one which is in fact obtained by a process as described above.
In preferred embodiments of this aspect the bacterium is one which is capable of introducing the above-described symptoms and disease of piscirickettsiosis, and wherein said bacteria have genotypic and/or phenotypic characteristics related to those of the above mentioned deposited isolates.
Use of sequences of genes encoding ribosomal RNAs and the internal transcribed spacers for characterisation of the bacterium according to the invention has been explained above. Accordingly, for the present aspect of the invention it may be preferred that the bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises a nucleic acid sequence which is more than 95% identical to the sequence of SEQ ID. NO. 1.
In further specific embodiments said bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises a nucleic acid sequence which is at least 95,0% identical to the sequence of SEQ ID. NO. 1, such as at least 95,1%, at least 95,2%, at least 95,3%, at least 95,4%, at least 95,5%, at least 95,6%, such as at least 95,7%, at least 95,8%, at least 95,9%, at least 96%, at least 97%, at least 98%, at least 99%, or such as at least 99.5% identical to the sequence of SEQ ID. NO. 1.
In further preferred embodiments said bacterium may be characterised by having an internal transcribed spacer region which comprises the sequence of SEQ ID NO: 1.
Additionally, said bacterium belonging to the Piscirickettsia genus is characterised by having a 16S rRNA gene which comprises a nucleic acid sequence which is at least 95,0% identical to the sequence of SEQ ID. NO. 2, such as at least 95,1%, at least 95,2%, at least 95,3%, at least 95,4%, at least 95,5%, at least 95,6%, such as at least 95,7%, at least 95,8%, at least 95,9%, at least 96%, at least 97%, at least 98%, at least 99%, or such as at least 99.5% identical to the sequence of SEQ ID. NO. 2.
In further specific embodiments said bacterium may be characterised by having a Comment [MR5]: re er i 16S rRNA gene, which comprises the sequence of SEQ ID NO: 2. | i e r e er d ide -de r e r e e er i d d rede if r e f rdi der i e rf e 1 In the currently most preferred embodiment of this aspect of the invention the e e er e e e i e e de der e re e bacterium is any of the representative isolates that have been deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the following accession numbers: 06050901 (isolate AL10005), 06050902 (isolate AL10007) and 06050903 (isolate AL10008), or the isolate which has been deposited on 21 March 2007 under the accession number 07032110 (isolate ALlOO 14).
Yet another main aspect of the invention pertains to a vaccine comprising a bacterium of the invention or a subunit of the bacterium. Within the scope of this aspect are vaccines based on concentrated and/or disrupted and/or inactivated bacteria. In certain aspects the vaccine may be based on attenuated bacteria.
In further preferred embodiments, the vaccine comprises an amount of antigen, which is higher than 0.05 mg/ml, such as from 0.05 to 5 mg/ml, from 0.1 to 4.5 mg/ml, from 0.2 to 4 mg/ml, from 0.3 to 3.5 mg/ml, from 0.4 to 3 mg/ml, from 0.4 to 3 mg/ml, from 0.5 to 2.5 mg/ml, from 0.6 to 2 mg/ml, from 0.7 to 1.5 mg/ml, or such as from 0.8 to 1 mg/ml.
In further preferred embodiments the vaccine is in a formulation comprising an adjuvant. Examples of adjuvants frequently used in fish and shellfish farming are muramyldipeptides, lipopolysaccharides, several glucans and glycans, mineral oil and Carbopol®. An extensive overview of adjuvants suitable for fish and shellfish vaccines is given in the review paper by Jan Raa (1996), the content of which is incorporated herein by reference in its entirety.
The vaccine of the invention may further comprise a suitable pharmaceutical carrier. In a currently preferred embodiment the vaccine is formulated as an emulsion of water in oil. The vaccine may also comprise a so-called "vehicle". A vehicle is a device to which the antigen adheres, without being covalently bound to it. Such vehicles are i.a. biodegradable nano/micro-particles or -capsules of PLGA (poly-lactide-co-glycolic acid), alginate or chitosan, liposomes, niosomes, micelles, multiple emulsions and macrosols, all known in the art. A special form of such a vehicle, in which the antigen is partially embedded in the vehicle, is the so- called ISCOM (European patents EP 109.942, EP 180.564 and EP 242.380, the content of which is incorporated herein by reference in its entirety).
In addition, the vaccine may comprise one or more suitable surface-active compounds or emulsifiers, e.g. Cremophore, Tween® and Span®. Also adjuvants such as interleukin, CpG and glycoproteins may be used. It is to be understood that the vaccine may further be in a formulation comprising an antigen from a bacterial source other than a bacterium of the Piscirickettsia genus, an antigenic material obtained from a viral source, an antigenic material obtained from a parasitical source, and/or an antigenic material obtained from a fungal source. In particular embodiments of the invention said antigen from a bacterial source other than bacterium of the Piscirickettsias genus is selected from the group consisting of live, attenuated or killed bacteria of the species, but not limiting to,
Aeromonas sp, Vibrio sp. Listonella sp., Moritella viscosa, Photobacterium damsela, Flavobacterium sp., Yersinia sp. Renibacterium sp. Streptococcus sp., Lactococcus sp., Leuconostoc sp., Bifidobacterium sp., Pediococcus sp., Brevibacterium sp., Edwarsiella sp. Francisella sp. Pseudomonas sp., Cytophaga sp., Nocardia sp., Mycobacerium sp., subunits of these bacteria, and any combination hereof.
Other specific embodiments pertain to a vaccine, wherein the antigenic material obtained from a viral source contained within the formulation is selected from the group consisting of Glycoprotein of Viral Hemorrhagic Septicemia Virus (VHSV); nucleoprotein of Viral Hemorrhagic Septicemia Virus (VHSV); glycoprotein of Infectious Hematopoietic Necrosis virus (IHNV); inactivated Pancreatc Necrosis Virus; VPl, VP2, VP3 or nucleoprotein structural proteins of Infectious Pancreatic Necrosis Virus (IPNV); G protein of Spring Viremia of Carp (SVC); and a membrane-associated protein, tegumin or capsid protein or glycoprotein of Channel Catfish Virus (CCV); and antigenic material obtained from ISA virus.
Further embodiments pertain to a vaccine, wherein said viral source is selected from the group consisting of pancreatic disease virus (SPDV), Iridovirus, Infectious Salmon Anaemia virus (ISAV), and heart and skeletal muscle inflammation virus. In preferred embodiments said parasitic source is selected from the group consisting of Lepeophtheirus Sp., Caligus Sp., and Ichthyophthirius Sp.
In other preferred embodiments the vaccine comprises an antigenic material obtained from a fungal source wherein said fungal source is selected from the group consisting of Saprolegnia Sp., Branchiomyces sanguinis, Branchiomyces demigrans and Icthyophonus hoferi.
In a presently most preferred embodiment the vaccine comprises antigenic amterial from Vibrio ordalii and Infectious Pancreatic Necrosis virus.
The vaccine according to the invention may in particular be formulated for administration to a fin fish. More specifically the vaccine may be (formulated) for administration to a telostei. The teleostei include, but are not limited to
salmonids, basses, breams, cods, snappers, flatfish, catfish, yellowtails and tilapias.
In further embodiments of the invention the vaccine is formulated for administration by a route selected from the group consisting of: Bath, immersion, intraperitoneal injection, intramuscular injection and oral administration. Optionally, the vaccine would be administered to young fish in the fresh-water stage..
In preferred embodiments of the invention the vaccine is one that is obtainable or one that is actually obtained by a process as described above. In a further aspect, the present invention provides a feed comprising the vaccine according to the invention, said feed may for example be pelleted or extruded feed.
Further aspects of the invention pertain to a bacterium according to the invention or a subunit hereof for use in veterinary medicine. Other aspects pertain to a bacterium according to the invention or a subunit of said bacteria in the manufacture of a medicament for the prevention of infections with bacteria of the Piscirickettsia genus. In particular a medicament comprising a bacterium according to the invention or a subunit hereof is relevant for the prevention of infections with Piscirickettsia salmonis or other species of the Piscirickettsia genus, hereunder for the prevention of piscirickettsiosis.
Finally, other aspects of the invention pertain to a method for prevention of infections in fish with bacteria of the Piscirickettsia genus, said method comprising administering to the fish a vaccine according to the invention.
With respect to the above description of the various aspects of the present invention and of the specific embodiments of these aspects it should be understood that any feature and characteristic described or mentioned above in connection with one aspect and/or one embodiment of an aspect of the invention also apply by analogy to any or all other aspects and/or embodiments of the invention described.
When an object according to the present invention or one of its features or characteristics is referred to in singular this also refers to the object or its features or characteristics in plural. As an example, when referring to "a vaccine" it is to be understood as referring also to one or more vaccines. Throughout the present specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. The following examples are included to demonstrate particular embodiments of the invention. However, those of skill in the art should, in view of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention. The following examples are offered by way of illustration and are not intended to limit the invention in any way.
The invention will now be described in further details in the following non-limiting examples and figure 1 to 4.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1: Data from experiment conducted to reveal the ability of P. salmonis to grow on traditional bacterial media.
Figure 2: Pulsed Field Electrophoresis gel showing a band pattern of the AL 10005 isolate of P. salmonis.
Figure 3: OD600 nm values for fermentation with and without pH control collected from experiments conducted in order to investigate if the use of controlled pH batch fermentation would increase the production of P. salmonis,
Figure 4: Cumulative % mortality of fish injected either with PBS or with a vaccine containing inactivated Piscirickettsia salmonis cultured by the method according to the invention.
EXAMPLES
Example 1. Isolation of P. salmonis from fish without the use of host cells.
Liver samples from moribund Atlantic salmon diagnosed with P. salmonis were aseptically removed and homogenised. The homogenate was diluted in SF900II cell culturing medium and centrifuged at 2000 x g to remove liver tissue. The clarified homogenate was inoculated in a dilution series in SF900II medium and incubated as static cultures at 18 degrees C. Bacterial growth could be observed within a few days. The bacterial suspension was identified to be P. salmonis by immunoflourescens microscopy using monoclonal antibodies as described in example 2.
Example 2. Identification of P. salmonis isolate.
The bacterial isolate was verified to be P. salmonis using a commercial kit "SRS Fluorotest Directo" from Bios Chile, Chile. The kit is based on FITC-conjugated monoclonal antibodies against P salmonis. Positive controls were slides with P. salmonis, fixed in methanol/acetone and frozen at -200C. Negative controls were slides with Aeromonas salmonicida, fixed in methanol/acetone and frozen at - 2O0C. Positive samples were observed as containing spherical fluorescent bacteria when viewed in a fluorescence microscope set at the appropriate wavelength.
Example 3: Propagation of P. salmonis without host cells.
Example 3 illustrates multiple passages of P. salmonis in spinner flasks, without the presence of host cells initiated from a frozen stock.
All the bacterial cultures were grown in SF900II media from Invitrogen with no supplements. The cultures were cultivated in ventilated spinner flasks at 75 rpm
and 20 degrees C. The growth was monitored by OD600 nm measurement and titration according to Karber, 1931 of the cultures.
The results shown in Table 1 clearly demonstrate the ability of P. salmonis to replicate without the presence of host cells. After approximately 6 days post resuscitation the bacteria reaches a typical growth pattern, and was sub cultured every 3-5th day. Maximum OD600 values of more than 7 were reached within 4-5 days. Table 1. Passage of P. sal in spinner flasks without Sf-9 cells in SF-900 II medium
Example 4: Growth of P. salmonis in different media
This experiment was conducted to reveal the ability of P. salmonis to grow on traditional bacterial media. Shaker flasks with different media compositions were prepared according to Table 2. The flasks were inoculated 1: 100 with passage 2 P. salmonis from a spinner flask. The cultures were incubated at 20 degrees C and with 100 rpm. ODεoo was measured daily. The results, which are presented in Figure 1, demonstrate that P. salmonis has the ability to replicate using traditional bacterial media, but the bacterial yield is higher when SF900II insect cell media is used.
Table 2: Medium composition
Example 5: 16S rRNA and ITS gene analysis, Pulsed field Gel Electrophoresis (PFGE) analysis of Piscirickettsia salmonis
Objective:
To analyse parts of both the spacer region between the 16S and 23S genes (internal transcribed spacer, ITS) and the 16S rRNA gene to be able to differentiate between species.
Method:
DNA was isolated from P.salmonis isolate AL10005, corresponding to the isolate deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the accession number 06050901 (grown with and without Sf-9 cells), and isolate LF-89 (ATCC VR1361). Primers were chosen to amplify parts of the 16S gene and the ITS using PCR. The PCR products were then sent for sequencing for comparison with known sequences in a gene bank.
16S rRNA:
Universal bacterial 16S primers were used in a first PCR, and then specific P.salmonis primers were used in a nested PCR to amplify a 467bp PCR product of the 16S rRNA gene according to Mauel, 1996.
ITS:
Specific P. salmonis primers were used to amplify a 236bp PCR product according to Marshall et al, 1998 .
The PCR products were sent to GATC Biotech for sequencing. The sequences were analysed using programme DNASIS Max and the comparison of the sequences were done at http://www.paraliqn.org/This service is based on the two comparison algorithms called Smith-Waterman (SW) and ParAlign. The first algorithm was published by Smith and Waterman (1981) and is a well established method that finds the optimal local alignment of two sequences The other algorithm, ParAlign, is a heuristic method for sequence alignment; details on the method is published in Rognes (2001). Default settings for score matrix and Gap penalties as well as E-values were used.
Result:
• 16S rRNA from AL10005 grown in Sf-9 cells:
ATCCATAGCTGGTTTGAGAGAATGGCCAGCCACACTGGGACTGAGACACGGCCCAGACT CCTACGGGAGGCAGCAGTGGGGAATATTGGACAATGGGGGAAACCCTGATCCAGCAAT GCCACGTGTGTGAAGAAGGCCTTAGGGTTGTAAAGCACTTTCAGCGGGGAGGAAGGTAA GCTAATTAATACTTGGCTTAATTGACGTTACCTGCAGAAGAAGCACCGGCTAACTCCGTG CCAGCAGCCGCGGTAATACGGAGGGTGCGAGCGTTAATCGGAATTACTGGGCGTAAAG GGCGCGTAGGCGGAAGATTAAGTTGGATGTGAAATCCCAGGGCTCAACCTTGGAACTGC ATCCGAAACTGGTATTCTAGAGTATGGTAGAGGAAAGTGGTTTCGCAGGTG (SEQ ID NO. 2)
• 16S rRNA from AL10005 grown without cells:
ATCCATAGCTGGTTTGAGAGAATGGCCAGCCACACTGGGACTGAGACACGGCCCAGACT CCTACGGGAGGCAGCAGTGGGGAATATTGGACAATGGGGGGAACCCTGATCCAGCAAT GCCACGTGTGTGAAGAAGGCCTTAGGGTTGTAAAGCACTTTCAGCGGGGAGGAAGGTAA
GCTAATTAATACTTGGCTTAATTGACGTTACCTGCAGAAGAAGCACCGGCTAACTCCGTG CCAGCAGCCGCGGTAATACGGAGGGTGCGAGCGTTAATCGGAATTACTGGGCGTAAAG GGCGCGTAGGCGGAAGATTAAGTTGGATGTGAAATCCCAGGGCTCAACCTTGGAACTGC ATCCGAAACTGGTATTCTAGAGTATGGTAGAGGAAAGTGGTTTCGCAGGTGTA (SEQ ID NO. 2)
• 16S rRNA from LF-89:
The sequence deposited in PubMed for the 16S rRNA gene of LF-89 (accession number U36941) was used for comparison with AL10005. Analysing the 16S rRNA sequences in Paralign show that these sequences match the LF89 16S rRNA gene between base pair 275 and 667, and the homology is 100%. The match with the EM-90 16S rRNA gene (accession number U36940) was 97%.
• ITS from AL10005 grown in Sf-9 cells: GTATAAGTAAAGATTCCTTGATTAATTTAGGGTTAI I I I I ATTTTCGATTGAGATGTATTTT
TATGTΠTGATTGATAAATGGGAATAA I I I I I AGTTTATTTAATTAACGAGTCTTGGTAATT TTTGAAAACCGGTGTTGAGATATAGTTTTGATTGGTTTTAGTTAATAGATTTTAGATTTATT
GATATAAGAC I I I I I GGGGTTATATGATCAAGTGAATAAGTGCAT (SEQ ID NO. 1)
• ITS from AL10005 grown without cells:
GTATAAGTAAAGATTCCTTGATTAATTTAGGGTTA i I I I I ATTTTCGATTGAGATGTATΠT
TATGTTTTGATTGATAAATGGGAATAA I I I I I AGTTTATTTAATTAACGAGTCTTGGTAATT TTTGMAACCGGTGTTGAGATATAGTTTTGATTGGTTTTAGTTMTAGATTTTAGATTTATT GATATAAGAC I I I I I GGGGTTATATGATCMGTGAATAAGTGCAT (SEQ ID NO. 1)
• ITS from LF89 grown in CHSE cells:
TTTAGGGTTA I I I I I AGtttacgttgagatgTA I I I I I ATGTCTTGATTGATTATTAGAAATMTT TTTAGTTTATTTMTTAACGAGTCTTGGTAAI I I I I GAMACCGGTGTTGAGATATAGTTTT GATTGGTATTAGTTAATAGATTTTAGATTTATTGATATMGACTTTTTGGGGTTATATGATC AAGTGAATAAGTGCa (SEQ ID NO. 3)
Comparison of the LF89 sequence with the AL10005 sequence show a 95% homology. Comparison with the Chilean isolate EM-90 ITS (accession nr U36944) show a 100% homology between EM-90 ITS and AL 10005 ITS.
Conclusion
This shows that Piscirickettsia salmonis isolates able to grow without the support of eukaryotic cells can be as little as 95% similar to the type strain LF-89.
PFGE analysis
Preparation of chromosomal DNA plugs and pulse field gel electrophoresis (PFGE). P.salmonis, strain AL 10007, was cultured in Sf 900-11 medium. Bacterial culture was concentrated by centrifugation (4000 x g, 10 min, 4°C), re-suspended and diluted in Cell Suspension Buffer (IM Tris, 0,5M EDTA, pH= 8.0). 25 μl Proteinase K (20 mg/ml) were added to 0, 5 ml cell suspension. Cells were embedded into 0.5 % agarose plugs by mixing the suspension 1:1 (v/v) with SeaKem Gold agarose (1 % in (w/v) in TE [IM Tris, 0,5M EDTA, pH= 8.0] ) and 5 % sodium dodecyl sulphate (20%).
The plugs were treated with lysis buffer (IM Tris, 0,5M EDTA, pH= 8.0) and 0, 5 % Proteinase K (20 mg/ml) at 54 0C for 2 hours. The plugs were washed two times with purified water for 10 minutes at 50 0C and two times with TE buffer for 15 minutes at 50 0C. Bam I, Xho I, Xba I, Ecori I, Age I, MIu I, Rsr II, Sma I, NcO I, Sac II, Kpn I, AfI III were used for restriction endonuclease digestion in accordance with the instructions of the manufacturers. The fragments were resolved by PFGE in SeaKem Gold agarose (1%) by using the CHEF Mapper XA system (Bio-Rad). The following parameters were used: running time 24 h; temperature, 14 0C; Voltage gradient, 6.0 V/cm, included angle, 120°; an initial pulse time of 0.1 s and a final pulse time of 15 s. The gel was stained with ethidium bromide (O.lμl/ml) for 30 min, distained in distilled water for 3x 30 minutes and photographed under UV light.
Results
A photo of the PFGE gel is shown in figure 2.
Lanes:
Enz ma Bam Xh Xb Eco Ag Ml Rsr Sm Nc Sac Kp AfI mar yme rke HI ol a RI el ul II al ol II nl III ker r
Lane 8 and 9 where DNA from AL 10007 is treated with enzymes Rsr I or Sma I displays how a PFGE band pattern from Piscirickettsia sp able to grow without the support of eukaryotic cells may appear.
Example 6: Fermentor culture
In order to investigate if the use of controlled pH batch fermentation would increase the production of P. salmonis, fermentation with and without pH control was initiated. OD600 nm was used to follow the production of bacteria and total protein was used to determined the final concentration of the cultures. The cultures were grown using SF900II media with no supplements in a lab scale fermentor with 1.51 working volume. The temperature was 20 degrees C. Stirring speed was kept between 100-400 rpm with aeration.
The pH was maintained using automatically addition of Sodium Hydroxide or Phosphoric acid.
The results from this experiment are presented in Figure 3 which clearly demonstrates that the bacterial yields are increased when cultured in a batch fermentor with a stabile pH of 6.5. Maximum OD600 values of more than 13 were reached within 5 days of cultivation.
Example 7: Detailed description of each step in the production process for Piscirickettsia salmonis without the support of eukaryotic cells.
P.sal.-01: Pre-culture no. 1
A flask containing 50-125 ml medium is inoculated with Working Seed suspension at a ratio of 0.5-2% of medium volume. The flask is incubated at a temperature of 19 ±2 CC
for 4-7 days or longer. The Optical Density (OD6oonm) of the culture at the moment of harvest will be at least 1.
The culture is transferred aseptically to the seed fermenter.
P.sal. -02: Pre-culture no. 2
A fermenter containing 7-9 litres of medium is inoculated with a suspension of pre-culture no. 1 at a ratio of 0.5-2% of medium volume. The culture is incubated at a temperature of 19 ±2 "C for a period of 2-4 days or longer until the culture has an Optical Density (OD6oonm) of at leastl.
During fermentation pH is adjusted to 6.2-6.5 with sodium hydroxide or phosphoric acid. Polypropylene glycol solution or 10% Pluronic (Polyoxyethylene-polyoxypropylene Block
Copolymer) solution is added automatically to control foaming.
The culture is transferred aseptically to the main fermenter.
P.sal. -03: Production culture
A fermenter containing 450 - 2000 litres of medium is inoculated with a suspension of pre-culture no. 2 at a ratio of 0.5-2% of medium volume. The culture is incubated at a temperature of 19 +2 0C. At regular intervals samples are taken to ensure that the culture is harvested in the logarithmic phase of the growth curve. The Optical Density (OD60onm ) of the culture at the moment of harvest will be between 6-14. This value is normally obtained after incubation for 3-6 days.
During fermentation pH is adjusted to 6.2-6.5 with sodium hydroxide or phosphoric acid. Polypropylene glycol solution or 10% Pluronic (Polyoxyethylene-polyoxypropylene Block Copolymer) is added automatically to control foaming.
The bacterial suspension is immediately inactivated.
P. sal, -04: Inactivation Formaldehyde solution (35 per cent) is added to the culture to a final concentration of 0.2% formaldehyde. The inactivant is thoroughly mixed with the bacterial suspension, which is then immediately transferred aseptically to the sterile inactivation tank. The culture is kept at a temperature of 19 ±2 0C during a period of 90 minutes under continuous agitation.
The inactivated bacterial suspension is transferred aseptically to the holding tank where the suspension is cooled. P.sal.-05: Concentration The inactivated P. salmonis suspension is concentrated by continuous cross flow filtration followed by diafiltration, using microfilters with a pore size of ≤ 0.2 μm.
During the processing all solutions in and out of the system are monitored by weight. The control of this mass balance ensures that the required concentration factor is achieved. During the diafiltration (2-3 x with PBS) the ingredients of the growth medium is partly substituted PBS.
The consistency is assured by the total protein measurement after concentration. This total protein is used to calculate the exact amount of concentrated antigen to be used in the vaccine.
Example 8: Immunisation of fish, and challenge with Piscirickettsia salmonis.
Vaccines
Piscirickettsia salmonis, isolate AL 10015 was grown in Sf900 II medium to an OD of 12.7 and inactivated with formalin. After inactivation, the antigen was diafiltrated and concentrated against PBS, resulting in an antigen solution with a protein content of 17.9 mg/ml. The antigen was formulated in mineral oil together with inactivated Vibrio ordalii and Infectious Pancreatic Necrosis virus. The Piscirickettsia salmonis antigen dose was 2.2 mg/ml vaccine.
Vaccination and challenge trial
Groups of 50 fish with an average weight of 34.6 grams were immunized intraperitoneal^ with a vaccine containing inactivated Piscirickettsia salmonis, Vibrio ordalii and Infectious Pancreatic Necrosis virus or phosphate buffered saline (PBS). The fish were kept at 120C and challenged intraperitoneally after 45 days with 1,33 x 104 TCID50 Piscirickettsia salmonis, isolate AL10007. The fish were followed for 42 days, and the number of mortalities in each group recorded.
Results
Figure 4 shows the cumulative % mortality of fish injected either with PBS or with a vaccine containing inactivated Piscirickettsia salmonis grown as described. The antigen was concentrated In the control group, 77.1% of the fish died, while 27.6 % of the fish died in the group vaccinated with a vaccine containing inactivated Piscirickettsia salmonis, Vibrio ordalii and Infectious Pancreatic Necrosis virus. This gives a relative % survival ({l-(%dead vaccinated group/% dead in control group)}*100) in the vaccinated group of 64.2. This experiment clearly shows that a vaccine produced with Piscirickettsia salmonis produced as described in this patent, mixed with other antigens reduced mortality against and elicits protection against piscirickettsiosis.
Example 9. Growth of Piscirickettsia salmonis on cystein heart agar supplemented with 5% sheep blood.
AL 10005 was inoculated onto cystein heart agar supplemented with 5% sheep blood. After one week incubation on 2O0C, bacterial growth was observed as whitish lines on the plates.
REFERENCES
"Affinity Chromatography; Principles and Methods", Edition AB, Published by
Amersham Pharmacia Biotech. Birkbeck T. H. et al. 2004, Infection and Immunity, VoI 72, 6, 3693-3694.
Bravo S & Campos M, 1989, Fish Health Section Newsletter, American Fisheries
Society 17, 3.
Cvitanich, Garate & Smith, 1991, J. Fish Diseases, Vol. 14, 121-145.
Fryer J. L. et al., 1990, Fish Pathology, Vol. 25, 2, 107-114. Fryer J. L. et al., 1992, International Journal of Systematic Bacteriology, Vol. 42,
1, 120-126.
Godwin, G.P. and Whitford, W., 1993, Focus® IS, 44.
House ML, Bartholomew JL, Winton JR and Fryer, 1999, Diseases of Aquatic
Organisms 35, 107-113. Jan Raa, 1996, Reviews in Fisheries Science 4(3): 229-228
Karber, G, 1931, Beitrag zur Kollektiven Behandlung Pharmakologischer
Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162:480-483.
Kuzyk M. A. et al., 2001a, J. MoI. Microbiol. Biotechnol. Vol. 3, 1, 83-93.
Kuzyk M. A. et al., 2001b, Vaccine, VoI 19, 2337-2344. Marshall S., Heath S., Henriquez V. & Orrego C, 1998, Minimally invasive detection of Pisάrickettsia salmonis in cultivated salmonids via the PCR. Appl.
Environ. Microbiol., 64, 3066-3069.
Mauel M. J., Giovannoni SJ. & Fryer J. L., 1996, Development of polymerase chain reaction assays for detection, identification, and differentiation of Pisciήckettsia salmonis. Dis. Aquat. Org., 26, 189-195.
McCarthy U, Steiropoulos, Thompson KD, Adams A, Ellis AE and Ferguson
HW,2005, Diseases of Aquatic Organisms 64, 107-119.
"Protein purification methods; a practical approach" Eds. ELV Harris and S Angal, published in the Practical Approach Series, series editors D Rickwood & BD Hames, IRL Press, Oxford 1989.
Rognes T, 2001, ParAlign: a parallel sequence alignment algorithm for rapid and sensitive database searches, Nucleic Acids Research, 29, 1647-1652.
Smith TF and Waterman MS, 1981, Identification of common molecular subsequences. Journal of Molecular Biology, 147, 195-197.
Smith PA, Lannan CN, Garces LH, Jarpa M, Larenas J, Caswell-Reno P, Whipple M and Fryer JL, 1995, Bulletin of the European Fish Pathologists 15, 137-141. Smith P. A., Contreras JR, Larenas JJ, Aguillon JC,Garces LH, Perez B and Fryer JL, 1997, Dev. Biol. Stand. Vol. 90, 161-166. World Organization for Animal Health as published in the Manual of Diagnostic tests for Aquatic Animals 2003, part 2, section 2.1, chapter 2.1.13
Claims
1. A process for culturing a bacterium belonging to the Piscirickettsia genus, wherein said bacterium is cultured in a substantially extracellular environment.
2. The process according to claim 1, wherein the bacterium belonging to the Piscirickettsia genus is cultured substantially in the absence of cells of nonbacterial origin.
3. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is of the species Piscirickettsia salmonis.
4. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is capable of introducing the symptoms and disease of piscirickettsiosis.
5. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus has genotypic and/or phenotypic characteristics related to those of the bacteria which are deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the following accession numbers: 06050901, 06050902 and 06050903 and the bacteria deposited on 21 March 2007 under the accession number 07032110 (isolate AL10014).
6. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises a nucleic acid sequence which is more than 95% identical to the sequence of SEQ ID. NO. 1 and/or by having a 16S rRNA gene, which is more than 95% identical to the sequence of SEQ ID. NO. 2.
7. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is characterised by having an internal transcribed spacer region which comprises the sequence of SEQ ID NO: 1.
8. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is further characterised by having a 16S rRNA gene, which comprises the sequence of SEQ ID NO: 2.
9. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is any of the bacteria, which are deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (LJK), SP4 OJG UK on
5 the 9 June 2006 under the following accession numbers: 06050901, 06050902 and 06050903 or the bacteria deposited on 21 March 2007 under the accession number 07032110 (isolate AL10014).
10. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is cultured in one or more pre-cultures
10 before being transferred to a production culture.
11. The process according to any of the preceding claims, wherein said bacterium belonging to the Piscirickettsia genus is cultured at a temperature of between 10 and 25°C.
12. The process according to any of the preceding claims, wherein the bacterium 15 belonging to the Piscirickettsia genus is propagated at a pH of between 5.5 and
8.0.
13. The process according to any of the preceding claims, wherein the bacterium belonging to the Piscirickettsia genus is cultured in a nutrition rich medium
14. The process according to any of the preceding claims wherein the bacterium 20 belonging to the Piscirickettsia genus is cultured by batch fermentation, by fed- batch fermentation or by continuous fermentation.
15. A process for producing a vaccine comprising one or more steps of culturing a bacterium of the Piscirickettsia genus, wherein the bacterium is cultured in a substantially extracellular environment.
25 16. The process according to claim 15, said process comprising the further steps of harvesting the bacterium from the culture medium; and/or concentrating the bacterium; and /or disrupting and/or inactivating the bacterium.
17. The process according to any of claims 15 and 16, said process comprising a step of attenuating the bacterium.
18. The process according to any of claims 16 and 17, wherein said step for concentrating the bacterium comprises the use of filtration techniques selected from the group consisting of: continuous cross flow filtration, diafiltration, centrifugation, separation or any combination hereof.
19. The process according to any of claims 15 to 18, said process comprising one or more steps for isolation and/or purification of a subunit the bacterium.
20. The process according to claim 19, wherein the isolation and/or purification of said subunit comprises one or more steps of affinity chromatography.
21. A process for obtaining a bacterium belonging to the Piscirickettsia genus, said process comprising the steps of: a) providing a sample from a fish, which is infected with bacteria belonging to the Piscirickettsia genus; b) inoculating into a essentially cell free culture medium bacteria from said sample or dilution series hereof, or bacteria from a spread plate culture established from said sample or dilution series hereof; and c) selecting a bacterium that propagate freely in the medium.
22. The process according to claim 21, wherein said sample is taken from a body tissue, a body fluid, a secretion or from a tissue homogenate.
23. A bacterium of the Piscirickettsia genus, said bacterium having the ability to propagate in a substantially extracellular environment.
24. The bacterium according to claim 23, said bacterium being obtainable by a process according to any of claims 21 and 22.
25. The bacterium according to any of claims 23 and 24, said bacterium having genotypic and/or phenotypic characteristics related to those of the bacteria which are deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 june 2006 under the following accession numbers: 06050901, 06050902, and 06050903 and the bacteria deposited on 21 March 2007 under the accession number 07032110 (isolate AL10014).
26. The bacterium according to any of claims 23 to 25, said bacterium being characterised by having an internal transcribed spacer region which comprises a nucleic acid sequence which is more than 95% identical to the sequence of SEQ ID. NO. 1 and/or by having a 16S rRNA gene, which is more than 95% identical to
5 the sequence of SEQ ID. IMO. 2.
27. The bacterium according to any of claims 23 to 26, said bacterium being characterised by having an internal transcribed spacer region which comprises the sequence of SEQ ID NO: 1.
28. The bacterium according to any of claims 23 to 27, said bacterium being
10 further characterised by having a 16S rRNA gene, which comprises the sequence Of SEQ ID NO: 2.
29. The bacterium according to any of claims 23 to 28, said bacterium being from any of the isolates, samples of which are deposited under the Budapest Treaty with the European Collection of Cell Culture (ECACC), Health Protection Agency,
15 Porton Down, Salisbury, Wiltshire (UK), SP4 OJG UK on the 9 June 2006 under the following accession numbers: 06050901, 06050902, and 06050903 or from the isolate a sample of which is deposited on 21 March 2007 under the accession number 07032110 (isolate AL10014).
30. A vaccine comprising a bacterium according to any of claims 23 to 29, or a 20 subunit of the bacterium.
31. The vaccine according to claim 30, said vaccine comprising an amount of antigen, which is higher than 0.05 mg/ml,
32. The vaccine according to any of claims 30 to 31, in a formulation comprising an adjuvant.
25 33. The vaccine according to claim 30 to 32 in a formulation comprising an antigen from a bacterial source other than a bacterium of the Piscirickettsia genus, an antigenic material obtained from a viral source, an antigenic material obtained from a parasitical source, and/or an antigenic material obtained from a fungal source.
34. The vaccine according to claim 33, wherein said antigen from a bacterial source other than bacterium of the Piscirickettsias genus is selected from the group consisting of live, attenuated or killed bacteria of the species but not limiting to Aeromonas sp., Vibrio sp., Listonella sp., Moritella viscosa, 5 Photobacterium damsela, Flavobacterium sp.. Yersinia sp., Renibacterium sp., Streptococcus sp., Lactococcus sp., Leuconostoc sp., Bifidobacterium sp., Pediococcus sp., Brevibacterium sp., Edwarsiella sp., Francisella sp., Pseudomonas sp., Cytophaga sp., Nocardia sp., Mycobacerium sp., subunits of these bacteria, and any combination hereof.
10 35. The vaccine according to claim 33, wherein said antigenic material obtained from a viral source is selected from the group consisting of Glycoprotein of Viral Hemorrhagic Septicemia Virus (VHSV); nucleoprotein of Viral Hemorrhagic Septicemia Virus (VHSV); glycoprotein of Infectious Hematopoietic Necrosis virus (IHNV); inactivated Pancreatc Necrosis Virus; VPl, VP2, VP3 or nucleoprotein
15 structural proteins of Infectious Pancreatic Necrosis Virus (IPNV); G protein of Spring Viremia of Carp (SVC); and a membrane-associated protein, tegumin or capsid protein or glycoprotein of Channel Catfish Virus (CC\/); antigenic material obtained from ISA virus.
36. The vaccine according to claim 33 and 34, wherein said viral source is selected 20 from the group consisting of pancreatic disease virus (SPDV), Iridovirus,
Infectious Salmon Anaemia virus (ISAV) and heart and skeletal muscle inflammation virus.
37. The vaccine according to claim 33, wherein said parasitic source is selected from the group consisting of Lepeophtheirus Sp., Caligus Sp., and
25 Ichthyophthirius Sp.
38. The vaccine according to claim 33, wherein said fungal source is selected from the group consisting of Saprolegnia Sp., Branchiomyces sanguinis, Branchiomyces demigrans and Icthyophonus hoferi.
30 39. The vaccine according to any of claims 30 to 38, said vaccine being formulated for administration to a fin fish.
40. The vaccine according to claim 30 to 38, said vaccine being formulated for administration to a telostei.
41. The vaccine according to any of claims 30 to 40, said vaccine being formulated for administration by a route selected from the group consisting of:
5 Bath, immersion, intraperitoneal injection, intramuscular injection and oral administration.
42. The vaccine according to any one of claims 30 to 41, said vaccine being obtainable by a process according to any of claims 15-22.
43. A feed comprising a vaccine according to any of claims 32 to 42.
10 44. A bacterium according to any of claims 23 to 33 or a subunit hereof for use in veterinary medicine.
45. Use of a bacterium according to any of claims 23 to 33 or a subunit of said bacterium in the manufacture of a medicament for the prevention of infections with bacteria of the Piscirickettsia genus.
15 46. A method for prevention of infections in fish with bacteria of the Piscirickettsia genus, said method comprising administering to the fish a vaccine according to any of claims 30 to 42.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0823188A GB2452892B (en) | 2006-06-29 | 2007-06-27 | Process for culturing bacteria of the piscirickettsia genus |
| CA2656032A CA2656032C (en) | 2006-06-29 | 2007-06-27 | Process for culturing bacteria of the piscirickettsia genus |
| NO20090442A NO20090442L (en) | 2006-06-29 | 2009-01-29 | Method of cultivating bacteria of the Piscirickettsia genus |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600888 | 2006-06-29 | ||
| DKPA200600888 | 2006-06-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2008002152A2 true WO2008002152A2 (en) | 2008-01-03 |
| WO2008002152A3 WO2008002152A3 (en) | 2008-03-06 |
| WO2008002152A8 WO2008002152A8 (en) | 2009-07-23 |
Family
ID=38686744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/NO2007/000239 WO2008002152A2 (en) | 2006-06-29 | 2007-06-27 | Process for culturing bacteria of the piscirickettsia genus |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA2656032C (en) |
| CL (1) | CL2007001893A1 (en) |
| GB (1) | GB2452892B (en) |
| WO (1) | WO2008002152A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2457158A (en) * | 2008-02-08 | 2009-08-12 | Pharmaq As | Polyvalent fish vaccines |
| WO2014198913A2 (en) * | 2013-06-14 | 2014-12-18 | Cermaq As | Novel piscirickettsia salmonis isolate |
| WO2016082050A1 (en) * | 2014-11-24 | 2016-06-02 | Pontificia Universidad Católica Del Valparaíso | Culture medium allowing the growth of the bacterium piscirickettsia salmonis |
| EP3241909A4 (en) * | 2014-12-30 | 2018-06-20 | Universidad De Chile | Pcr-rflp-based method for identifying, and determining the purity of piscirickettsia salmonis |
| WO2024003035A1 (en) | 2022-06-27 | 2024-01-04 | Vaxxinova Norway As | Vaccines for piscirickettsiosis (salmonid rickettsial septicaemia) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9993541B2 (en) | 2013-11-13 | 2018-06-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
-
2007
- 2007-06-27 WO PCT/NO2007/000239 patent/WO2008002152A2/en active Search and Examination
- 2007-06-27 CL CL2007001893A patent/CL2007001893A1/en unknown
- 2007-06-27 GB GB0823188A patent/GB2452892B/en active Active
- 2007-06-27 CA CA2656032A patent/CA2656032C/en active Active
Non-Patent Citations (5)
| Title |
|---|
| BIRKBECK T HARRY ET AL: "Growth of Piscirickettsia salmonis to high Titers in insect tissue culture cells" INFECTION AND IMMUNITY, vol. 72, no. 6, June 2004 (2004-06), pages 3693-3694, XP002459547 ISSN: 0019-9567 * |
| CVITANICH J D ET AL: "THE ISOLATION OF A RICKETTSIA-LIKE ORGANISM CAUSING DISEASE AND MORTALITY INCHILEAN SALMONIDS AND ITS CONFIRMATION BY KOCH'S POSTULATE" JOURNAL OF FISH DISEASES, OXFORD, GB, vol. 14, no. 2, 1991, pages 121-146, XP009092260 ISSN: 0140-7775 * |
| FRYER J L ET AL: "ISOLATION OF A RICKETTSIALES-LIKE ORGANISM FOR DISEASED COHO SALMON (ONCORHYNCHUS KISUTCH) IN CHILE" FISH PATHOLOGY, XX, JP, vol. 25, no. 2, 1990, pages 107-114, XP001206465 * |
| FRYER J L ET AL: "PISCIRICKETTSIA SALMONIS GEN. NOV., SP. NOV., THE CAUSATIVE AGENT OF AN EPIZOOTIC DISEASE IN SALMONID FISHES" INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 42, no. 1, January 1992 (1992-01), pages 120-126, XP001029383 ISSN: 0020-7713 * |
| FRYER J L ET AL: "Piscirickettsia salmonis: A Gram-negative intracellular bacterial pathogen of fish" JOURNAL OF FISH DISEASES, OXFORD, GB, vol. 26, no. 5, 20 May 2003 (2003-05-20), pages 251-262, XP002253317 ISSN: 0140-7775 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2457158A (en) * | 2008-02-08 | 2009-08-12 | Pharmaq As | Polyvalent fish vaccines |
| GB2457158B (en) * | 2008-02-08 | 2013-04-03 | Pharmaq As | Polyvalent vaccine against salmonid alphavirus infections |
| WO2014198913A2 (en) * | 2013-06-14 | 2014-12-18 | Cermaq As | Novel piscirickettsia salmonis isolate |
| WO2014198913A3 (en) * | 2013-06-14 | 2015-02-26 | Cermaq As | Novel piscirickettsia salmonis isolate |
| GB2530210A (en) * | 2013-06-14 | 2016-03-16 | Cermaq As | Novel piscirickettsia salmonis isolate |
| GB2530210B (en) * | 2013-06-14 | 2017-12-27 | Cermaq Group As | Novel piscirickettsia salmonis isolate |
| WO2016082050A1 (en) * | 2014-11-24 | 2016-06-02 | Pontificia Universidad Católica Del Valparaíso | Culture medium allowing the growth of the bacterium piscirickettsia salmonis |
| EP3241909A4 (en) * | 2014-12-30 | 2018-06-20 | Universidad De Chile | Pcr-rflp-based method for identifying, and determining the purity of piscirickettsia salmonis |
| WO2024003035A1 (en) | 2022-06-27 | 2024-01-04 | Vaxxinova Norway As | Vaccines for piscirickettsiosis (salmonid rickettsial septicaemia) |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2656032A1 (en) | 2008-01-03 |
| GB2452892B (en) | 2011-10-12 |
| GB0823188D0 (en) | 2009-01-28 |
| WO2008002152A3 (en) | 2008-03-06 |
| GB2452892A (en) | 2009-03-18 |
| CA2656032C (en) | 2017-06-13 |
| WO2008002152A8 (en) | 2009-07-23 |
| CL2007001893A1 (en) | 2008-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Romalde | Photobacterium damselae subsp. piscicida: an integrated view of a bacterial fish pathogen | |
| KR20060054352A (en) | Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof | |
| CA2656032C (en) | Process for culturing bacteria of the piscirickettsia genus | |
| CN1930185A (en) | Canine vaccine for protection against ehrlichiosis | |
| CN109195623A (en) | 2 type of chimeric porcine circovirus type (PCV2) vaccine | |
| EP2187958B1 (en) | Attenuated ehrlichiosis vaccine | |
| JP5087604B2 (en) | Novel bacteria responsible for poultry disease and vaccines derived therefrom | |
| EP3071226B1 (en) | Fish vaccine | |
| DK180623B1 (en) | Fish virus | |
| CN113862230A (en) | Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof | |
| CN112226379A (en) | Erysipelothrix rhusiopathiae type 1a strain, swine erysipelas inactivated vaccine and application thereof | |
| CN103602637B (en) | Vaccine strain for mycoplasma pneumonia of swine | |
| CN110859956B (en) | Canine parvovirus inactivated vaccine and preparation method thereof | |
| CN110846284B (en) | Canine parvovirus CPV-HuN1703 strain and application thereof | |
| CN113151078A (en) | Salmonella enteritidis outer membrane vesicle, preparation method and application thereof as avian salmonellosis subunit vaccine | |
| JP2005511032A5 (en) | ||
| AU2002363173A1 (en) | New bacterium causing poultry disease and vaccine derived thereof | |
| Dadar et al. | Isolation and phylogenic analysis of emerging new antibiotic resistant bacteria, Acinetobacter lwoffii, associated with mortality in farmed rainbow trout | |
| ELIASSEN et al. | Sommaire du brevet 2656032 | |
| CA2915211C (en) | Novel piscirickettsia salmonis isolate | |
| KR101210082B1 (en) | Vaccine composition for swine polyserositis and manufacturing method thereof | |
| ELIASSEN et al. | Patent 2656032 Summary | |
| KR101209964B1 (en) | Vaccine composition for swine polyserositis and manufacturing method thereof | |
| CN110124022A (en) | A kind of mycoplasma hyopneumoniae and haemophilus parasuis, Streptococcus suis, Actinobacillus pleuropneumoniae tetrad inactivated vaccine and its application | |
| CN112694988B (en) | Chicken source streptococcus suis attenuated strain and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07768940 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
| ENP | Entry into the national phase in: |
Ref document number: 0823188 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20070627 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 0823188.8 Country of ref document: GB |
|
| ENP | Entry into the national phase in: |
Ref document number: 2656032 Country of ref document: CA |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07768940 Country of ref document: EP Kind code of ref document: A2 |
|
| DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |